意义未明的单克隆丙种球蛋白病 中国就医指南

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a premalignant plasma cell disorder characterized by the presence of a monoclonal (M-) protein in serum (<3 g/dL), bone marrow plasma cells <10%, and absence of end-organ damage—such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB features)—or other B-cell lymphoproliferative disorders. MGUS is not cancer, but it represents a biologically heterogeneous clonal expansion of plasma cells with inherent risk of progression to multiple myeloma, Waldenström macroglobulinemia, AL amyloidosis, or lymphoplasmacytic lymphoma. Pathogenesis involves early genetic alterations—including IGH translocations, del(13q), +1q, and mutations in KRAS, NRAS, and DIS3—occurring in long-lived plasma cells or memory B-cells, often driven by chronic immune stimulation, aging-related genomic instability, and dysregulated bone marrow microenvironment signaling (e.g., IL-6, BAFF, APRIL). Epidemiologically, MGUS prevalence rises sharply with age: ~3% in adults aged 50–70 years and >5% in those over 70; it is slightly more common in males and individuals of African descent. Risk factors include advanced age, male sex, Black race, family history of plasma cell disorders, autoimmune conditions (e.g., rheumatoid arthritis), chronic infections, and occupational exposures (e.g., pesticides, solvents). Importantly, MGUS itself is asymptomatic—patients do not experience fatigue, bone pain, recurrent infections, or neuropathy *due to MGUS alone*. However, its diagnosis triggers lifelong monitoring anxiety, repeated blood tests, and occasional bone marrow evaluations, contributing to measurable psychological burden and health-related quality of life (HRQoL) impacts—particularly in older adults managing comorbidities. While MGUS does not require treatment, misperception of malignancy risk can lead to unnecessary distress, overtreatment, or avoidance of routine care. Surveillance remains the cornerstone: serum protein electrophoresis (SPEP), free light chain assay, and clinical assessment every 6–12 months for stable cases. Risk stratification (e.g., Mayo Clinic or Spanish PETHEMA models) guides monitoring intensity based on M-protein type, level, free light chain ratio, and immunoglobulin isotype. Early detection of progression allows timely intervention, improving outcomes in subsequent malignancies. As such, MGUS exemplifies the critical role of hematologic vigilance in preventive oncology—balancing reassurance with evidence-based surveillance to preserve both physical health and psychosocial well-being.

# 意义未明的单克隆丙种球蛋白病（MGUS）治疗方案与费用明细（血液科）

一、非手术/保守管理方案（适用所有MGUS患者）

• •适用人群：血清M蛋白＜30 g/L、无终末器官损害（肾功能正常、无贫血/骨破坏/高钙血症）、无症状者
• •核心措施：每6–12个月随访（血清蛋白电泳+免疫固定电泳+游离轻链+全血细胞计数+肌酐+β2微球蛋白）
• •年均费用区间：¥1,800–¥3,200（含基础检验费¥1,200–¥2,000；门诊诊查费¥600–¥1,200）

二、药物干预方案（仅限进展高危或转化前兆者）

• •适用人群：高危MGUS（IgA/IgM型、M蛋白≥15 g/L、FLC比值异常、骨髓浆细胞≥5%）
• •方案：观察为主，暂无获批一线药物；临床试验入组可选（如来那度胺单药维持）
• •年费用区间：¥0（标准管理）；入组GCP试验免费；自费参与扩展用药约¥45,000–¥68,000/年

三、手术/介入方案

• •不适用：MGUS为前恶性克隆状态，无手术指征；骨病/神经病变等并发症按原发病处理，非MGUS本身治疗手段

四、特殊复杂情况处理

• •继发性淀粉样变/POEMS综合征/多发性骨髓瘤转化：转入多发性骨髓瘤路径，费用依方案而定（如RVd方案首年约¥85,000–¥120,000）

方案快速选择指南

• •预算有限/初筛确诊者 → 保守随访（¥2,500/年）
• •高危特征但无症状者 → 强化监测+专科评估（¥4,000/年）
• •已转化或合并靶器官损伤者 → 启动血液肿瘤规范诊疗路径